Use of enzyme immunoassay for measurement of skeletal troponin-I utilizing isoform-specific monoclonal antibodies
References (21)
- et al.
Changes in serum myoglobin, total creatine kinase, lactate dehydrogenase and creatine kinase MB levels in runners
Clin Biochem
(1983) - et al.
Cardiac specific troponin-I release in canine experimental myocardial infarction: Development of a sensitive enzyme-linked immunoassay
J Mol Cell Cardiol
(1987) - et al.
Sequencing of a cDNA encoding the human fast-twitch skeletal muscle isoform of troponin I
Biochim et Biophys Acta
(1994) - et al.
cDNA sequence, tissue specific expression and chromosomal mapping of the human slow-twitch skeletal muscle isoform of troponin I
Genomics
(1990) - et al.
Cardiac abnormalities in polymyositis/dermatomyositis
Semin Arthritis Rheum
(1982) - et al.
The heart and cardiac conduction system in polymyositis-dermatomyositis: A clinicopathologic study of 16 autopsied patients
Am J Cardiol
(1982) Enzymes and routine diagnosis
- et al.
Dual-label time-resolved fluoroimmunoassay for simultaneous detection of myoglobin and carbonic anhydrase III in serum
Clin Chem
(1991) - et al.
Effect of training on eccentric exercise-induced muscle damage
J Appl Physiol
(1993) - et al.
Levels of serum creatine kinase and myoglobin in women after two isometric exercise conditions
Eur J Appl Physiol
(1986)
Cited by (28)
The Troponin-I fast skeletal muscle is reliable marker for the determination of vitality in the suicide hanging
2019, Forensic Science InternationalCitation Excerpt :The commonly used serum markers, e.g., lactate dehydrogenase, creatine kinase (CK), 1 and myoglobin, lack specificity to skeletal tissue. Several groups [11–14] used immunoassays to investigate use of the skeletal isoform of troponin I (sTnI) as a marker of skeletal muscle injury, just as its cardiac isoform (cTnI) is currently the gold standard for detecting cardiac muscle injury [15]. sTnI exists as 2 different isoforms, slow sTnI (ssTnI) and fast sTnI (fsTnI), produced in slow- (ST) and fast-twitch (FT) fibers, respectively.
Biomarker panel of cardiac and skeletal muscle troponins, fatty acid binding protein 3 and myosin light chain 3 for the accurate diagnosis of cardiotoxicity and musculoskeletal toxicity in rats
2012, ToxicologyCitation Excerpt :Therefore, while increases in these conventional biomarkers make it possible to detect a broad spectrum of organ toxicity, these biomarkers cannot discriminate between specific organ toxicities. In order to complement the low tissue specificity, several promising biomarkers such as cardiac and skeletal muscle troponins (cTnI, cTnT and sTnI), fatty acid binding protein-3 (FABP3) and myosin light chain-3 (MYL3, also known as MLC1V) have also been adapted for clinically monitoring patients (Colli et al., 2007; Keller et al., 2009; Hillis et al., 2003; Matziolis et al., 2011; Pelsers et al., 2005; Ravkilde et al., 1995; Reichlin et al., 2009; Simpson et al., 2005; Takahashi et al., 1996). Therefore, the reverse-translational application of these promising biomarkers in experimental animals could potentially improve the detection power for diagnosing cardiotoxicity and musculoskeletal toxicity, in addition to helping predict the occurrence of these toxicities in humans.
Electrochemiluminescent immunoassay for rat skeletal troponin I (Tnni2) in serum
2010, Journal of Pharmacological and Toxicological MethodsSkeletal troponin-I release in orthopedic and soft tissue injuries
2001, Journal of Orthopaedic ScienceBiomarkers in glycogen storage diseases: An update
2021, International Journal of Molecular Sciences